Cureshank CureSHANK has a singular purpose: To accelerate the development of treatments for Phelan-McDermid Syndrome and SHANK-related disorders. Our approach is to identify and fund projects that overcome critical barriers to successful drug development and to coordinate scientific efforts to improve efficiency and speed in the field.
Cureshank has received 19 grants from 14 known foundation funders. Revenue increased from $464,972 in 2023 to $597,811 in 2024. Most recent reported revenue: $597,811.
Annual Revenue
$597,811
Known Funders
14
Grants Received
19
Financial History
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2024 | $597,811 | $528,155 | $1,118,841 |
| 2023 | $464,972 | $287,968 | $1,042,385 |
| 2022 | $487,302 | $219,660 | $854,048 |
| 2021 | $547,552 | $18,174 | $586,406 |
Top Funders
MELBOURNE, FL
NEW YORK, NY
HOUSTON, TX
BEVERLY HILLS, CA
LOS ANGELES, CA
BOSTON, MA
PENNINGTON, NJ
NEW YORK, NY
LOS ANGELES, CA
AGOURA HILLS, CA
Showing top 10 of 14 funders.
Key Personnel
From 2024 IRS 990 filing
Geraldine Bliss
President
Talya Emery Silva
Vice President
Abby Lievense
Treasurer
Laura Hinrichsen
Secretary
Grace Li
Director
Jenny Graham Beeson
Director
Laura Hinrichsen
Director
Paulina Rychenkova
Director
Frequently Asked Questions
Other Nonprofits in California
Unlock Full Nonprofit Data
Sign up for free to access the complete funder list, financial history, program details, key personnel, and smart matching.